CRIMEAN-CONGO HEMORRHAGIC-FEVER TREATED WITH ORAL RIBAVIRIN
CRIMEAN-CONGO HEMORRHAGIC-FEVER TREATED WITH ORAL RIBAVIRIN
复制标题
DOI：
10.1016/s0140-6736(95)91323-8
复制
发表时间：
1995-08-19
期刊：
影响因子：
168.9
通讯作者：
MCCORMICK, JB
中科院分区：
文献类型：
--
作者：
FISHERHOCH, SP;KHAN, JA;MCCORMICK, JB
克里米亚-刚果出血热 (CCHF) 是一种由蜱传病毒引起的致命出血热。尽管已确定体外和体内敏感性，但尚无关于利巴韦林治疗 CCHF 感染患者的公开数据。我们报告了巴基斯坦感染 CCHF 病毒的三名卫生工作者（两名外科医生和一名医院工作人员），他们接受口服利巴韦林 4 克/天治疗四天，然后口服利巴韦林 2.4 克/天治疗六天。无法静脉注射利巴韦林。所有三名患者均病情严重，血小板和白细胞计数较低，天冬氨酸转氨酶升高表明止血功能受损。根据已发表的报告，所有人的死亡概率估计为 90% 或更高。患者在利巴韦林治疗后48小时内不再发热，血液学和生化异常恢复正常；所有患者均完全康复，并产生了针对 CCHF 病毒的 IgG 和 IgM 抗体。我们使用利巴韦林治疗的经验令人鼓舞，但并不构成疗效的证据。鉴于收集足够治疗数据的困难，我们提出了 CCHF 静脉内和口服治疗的共识方案。该方案可以分发给 CCHF 流行地区的主要医务人员，并用于为有效的治疗建议提供坚实的基础。
Crimean-Congo Haemorrhagic Fever (CCHF) is an often-lethal haemorrhagic fever caused by a tick-borne virus. There are no published data on ribavirin treatment of CCHF-infected patients, despite established in-vitro and in-vivo sensitivity.We report three health workers-two surgeons and a hospital worker-infected with CCHF Virus ill Pakistan who were treated with oral ribavirin 4 g/day for four days, then 2.4 g/day for six days. Intravenous ribavirin was unavailable. All three patients were severely ill with low platelet and white-cell counts, raised aspartate transaminase acid evidence of impaired haemostasis. Based on published reports, all had an estimated probability of death of 90% or more. The patients became afebrile, and their haematological and biochemical abnormalities returned to normal within 48 h of ribavirin treatment; all made a complete recovery, and developed IgG and IgM antibody to CCHF virus.Our experience with ribavirin treatment is encouraging, but does not constitute evidence of efficacy. Given the difficulties in gathering adequate treatment data, we propose a consensus protocol for both intravenous and oral treatment of CCHF. This protocol could be distributed to key medical personnel in areas endemic for CCHF and used to provide a firm basis for effective treatment recommendations.